Sons And Daughters BBCMF Bird Flu Pandemic Biotechnology

[mick]

one more news item for XLPI

Xcelplus Asian Flu Update
Wednesday November 30, 4:16 pm ET


SALUDA, Va.--(BUSINESS WIRE)--Nov. 30, 2005--XcelPlus International Inc. (Pink Sheets: XLPI - News), XcelPlus International (http://XcelPlus.com) is preparing to enter into agreements for the distribution of our Asian flu products in Canada and India, in addition to new dealers and distributors in Asia through Xcelplus Asia Pacific.
ADVERTISEMENT


Our potential new Canadian distributor has asked for an exclusive territory, being all of Canada with options for other countries.

In India, two companies and possibly a third are vying for distributorships for the countries of India and Sri Lanka due their ties there and support of Xcel's product to help fight and control the Avian Flu virus.

The managing Director for Xcelplus Asia Pacific has returned from China and has distributorship interest for Asian Flu / Sars products as well as the Xcelplus line of products for automobiles, industrial use as well as the motorbike markets.

There will be two products released for the Avian Flu virus. The first will be sprayed on the ground and cages where the birds feed and live. This product which was named Eliminator 200(TM) will also be used to spray truck and car tires that are leaving poultry farms as well as possibly vehicles entering into various countries to stop the spread of the virus across borders.

The second product is called Xcelplus FAM-415(TM) (Food Anti-Microbial) and will be marketed in two forms as a wash for the birds and as a drink that the birds can ingest. These two products used in tandem should help control the spread of the virus by killing the virus at its source. The FAM-415 should also stop the spread to humans. The virus is usually spread by direct contact with infected birds.

According to the Center for Disease Control (CDC) the Avian Flu is passed to humans through direct contact and handling of infected birds. These infected birds, ducks, chickens and turkeys pass it to each other through excretions/secretions that are contaminated with the virus.

The risk from avian influenza is generally low to most people because the viruses occur mainly among birds and do not usually infect humans. However, more than 100 human cases of avian influenza infection have been reported since 1997. Most cases of avian influenza infection in humans have resulted from contact with infected poultry (e.g., domesticated chicken, ducks, and turkeys) or surfaces contaminated with secretion/excretions from infected birds.

Infected birds shed influenza virus in their saliva, nasal secretions, and feces. Susceptible birds become infected when they have contact with contaminated secretions or excretions or with surfaces that are contaminated with secretions or excretions from infected birds. Domesticated birds may become infected with avian influenza virus through direct contact with infected waterfowl or other infected poultry, or through contact with surfaces (such as dirt or cages) or materials (such as water or feed) that have been contaminated with the virus.

Xcelplus with these two new products will be able to kill the virus at its source, on the birds where there is the most risk to humans and other birds.

Other pertinent information on the virus can be found on the CDC website at http://www.cdc.gov/flu/avian/gen-info/facts.htm

This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities and Exchange Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainties. Although XcelPlus International believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any assumption could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion should not be regarded as a representation by XcelPlus International Inc or any other person that the objective and plans of XcelPlus International Inc will be achieved.



Contact:
XcelPlus International Inc., Investor Relations
Brad Novak, 949-661-5780
[e-mail]
http://XcelPlus.com

--------------------------------------------------------------------------------
Source: XcelPlus International Inc.


Email Story
Set News Alert
Print Story